Changes between Version 10 and Version 11 of Research/DesignStudy/SteeringGroup/2020-07-03


Ignore:
Timestamp:
Jul 3, 2020, 3:50:11 PM (4 years ago)
Author:
longkr
Comment:

--

Legend:

Unmodified
Added
Removed
Modified
  • Research/DesignStudy/SteeringGroup/2020-07-03

    v10 v11  
    8888----
    8989
     90== Agenda ==
     91
     921. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:]
     93 * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     94  * **Ongoing.**  Need to step up the priority of this activity as we prepare the EPSRC proposal.
     95 * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     96  * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast.
     97 * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     98  * **Stands.** Agenda item.
     99 * **KL** Send out diary invitation straight away to get it into the diary.
     100  * **Done.**
     101
     1022. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\
     103
     1043. Discussion of SG composition: KL/All
     105
     1064. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All
     107 * Dealing with feedback from our 2019 submission: \\
     108   "//Engagement with patients, clinicians and industry could have been strengthened//"
     109  - Patient engagement:
     110   - Actions taken to date;
     111   - Need for local action by partner;
     112   - Subsequent coordination
     113  - Clinician engagement:
     114   - Actions taken to date;
     115   - Need for local action by partner;
     116   - Subsequent coordination
     117  - Industrial engagement:
     118   - Actions taken to date;
     119   - Discussion of next steps
     120 * Slides to initiate discussion of:
     121  - Scope;
     122  - Initial discussion of work packages;
     123  - Stakeholders from whom we should be seeking support;
     124 * Next steps discussion
     125 
     1265. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all
     127
     1286. DONMs \\
     129 * 04 Sep 2020; 10:00 BST
     130
     1317. AoB \\
     132 
     133----